George Zhang

TL;DR: Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration.

TL;DR: Coadministration of the P-gp inhibitors quinidine, verapamil, and dronedarone increased edoxaban exposure and Modest/minimal effects were observed for amiodarone, atorvastatin, and digoxin.

TL;DR: It is suggested that while oral edoxaban is an appropriate alternative to subcutaneous dalteparin for treatment of cancer-associated VTE, the use of Edoxaban in patients with gastrointestinal cancer requires careful benefit-risk weighting.

TL;DR: The primary efficacy outcome was the proportion of patients with symptomatic recurrent venous thromboembolism during the 12-month study period, analysed in the modified intention-to-treat population, with an upper limit of the CI for the hazard ratio (HR) of 1·5.

TL;DR: Edoxaban has a similar risk-benefit ratio to dalteparin in most cancer groups, and in those with gastrointestinal cancer, the lower risk of recurrent VTE and the advantages of oral therapy need to be balanced against the increased risk of major bleeding.